Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report

As Acelyrin’s shareholders prepare for the company’s planned merger with Alumis, they now have another option that could upend the deal: a $3-per-share offer from Tang Capital-backed Concentra that also includes a CVR.

According to Concentra Biosciences LLC’s Feb. 20 offer letter, shareholders of Acelyrin Inc. (NASDAQ:SLRN) have until Thursday evening to make a decision whether to accept the new offer. They would receive a premium: Acelyrin closed at $2.17 on Thursday, Feb. 20, before the proposal came to light, and traded at about $2.60 on Monday...